---
figid: PMC4024346__nihms577761f2
figlink: /pmc/articles/PMC4024346/figure/F2/
number: Figure 2
caption: Phosphorylation of the activation loop serines on MEK1 and 2 decreases affinity
  for allosteric inhibitors such as trametinib and selumetinib. MEK1 T292 is a phosphorylation
  site for ERK1/2 that negatively regulates MEK1 kinase activity. MEK2 lacks this
  negative feedback regulatory site and is not feedback inhibited by ERK1/2 dependent
  phosphorylation.
pmcid: PMC4024346
papertitle: 'Molecular Pathways: Adaptive Kinome Reprogramming in Response to Targeted
  Inhibition of the BRAF-MEK-ERK Pathway in Cancer.'
reftext: Gary L. Johnson, et al. Clin Cancer Res. ;20(10):2516-2522.
pmc_ranked_result_index: '22257'
pathway_score: 0.8670788
filename: nihms577761f2.jpg
figtitle: Phosphorylation of the activation loop serines on MEK1 and 2 decreases affinity
  for allosteric inhibitors such as trametinib and selumetinib
year: ''
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4024346__nihms577761f2.html
  '@type': Dataset
  description: Phosphorylation of the activation loop serines on MEK1 and 2 decreases
    affinity for allosteric inhibitors such as trametinib and selumetinib. MEK1 T292
    is a phosphorylation site for ERK1/2 that negatively regulates MEK1 kinase activity.
    MEK2 lacks this negative feedback regulatory site and is not feedback inhibited
    by ERK1/2 dependent phosphorylation.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - BRAF
  - NRAS
  - KRAS
  - ARAF
  - MAPK1
  - HRAS
  - MAPK3
  - MAP2K2
  - MAP2K1
  - RAF1
  - Trametinib
  - Cancer
  - Cardiomyopathy
  - Noonan syndrome
genes:
- word: RTKSdriveRas/BRaf
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: Ras/BRaf
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: Ras/BRaf
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: ERK2
  symbol: ERK2
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: Ras/BRaf
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: ERK1/2
  symbol: ERK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: MEK1/2
  symbol: MEK2
  source: hgnc_alias_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: MEK1/2
  symbol: MEK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: Raf
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
chemicals:
- word: Trametinib
  source: MESH
  identifier: C560077
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
---
